Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
Afsaneh Shirani, MD; Yinshan Zhao, PhD; Mohammad Ehsanul Karim, MSc; Charity Evans, PhD; Elaine Kingwell, PhD; Mia L. van der Kop, MSc; Joel Oger, MD, FRCPC; Paul Gustafson, PhD; John Petkau, PhD; Helen Tremlett, PhD
JAMA. 2012;308(3):247-256. doi:10.1001/jama.2012.7625
"In conclusion, we did not find evidence that administration of interferon beta was associated with a reduction in disability progression in patients with relapsing-remitting MS. The ultimate goal of treatment for MS is to prevent or delay long-term disability. Our findings bring into question the routine use of interferon beta drugs to achieve this goal in MS."
read the full paper: http://jama.jamanetwork.com/article.aspx?articleid=1217239


JAMA Network | JAMA: The Journal of the American Medical Association | Association Between Use of In
jama.jamanetwork.com
Author Affiliations: Division of Neurology and Brain Research Centre, Department of Medicine and Vancouver Coastal Health Research Institute (Drs Shirani, Evans, Kingwell, Oger, and Tremlett and Ms van der Kop), Division of Neurology, Department of Medicine, MS/MRI Research Group (Dr Zhao), and Depa...